Ramucirumab Plus FOLFIRI Versus Ramucirumab Plus Paclitaxel in Patients With Advanced or Metastatic Gastric Cancer, Who Failed One Prior Line of Palliative Chemotherapy

NCT03081143 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

429

Enrollment

OTHER

Sponsor class

Conditions

Advanced Gastric or EGJ Cancer

Interventions

DRUG: FOLFIRI
DRUG: Ramucirumab
DRUG: Paclitaxel

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest